Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildacerfont for glucocorticoid reduction in adults with classic congenital adrenal hyperplasia
2023-503771-13-00Phase 2Completed
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial in classic congenital adrenal hyperplasia comparing Tildacerfont plus background glucocorticoid therapy with Placebo plus background glucocorticoid therapy (2 arms). Primary endpoint: Absolute change from baseline in glucocorticoid dose in hydrocortisone equivalents at Week 24. Started Apr 2023; status: completed.
02
Drugs
tildacerfont
03
Conditions
classic congenital adrenal hyperplasia
Beyond the preview
Go deeper on 2023-503771-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503771-13-00.